BioSpace News Archive

Henry Schein, Inc. (Nasdaq: HSIC) today announced its lineup of products and solutions at the American Association of Oral and Maxillofacial Surgeons (AAOMS) Annual Conference in New Orleans, La. from September 12 through September 17.

Verge Genomics announced that Fierce Biotech named it as a 2022 “Fierce 15” recipient, a recognition given to the biopharmaceutical industry’s most promising early-stage companies.

Cellics Therapeutics, Inc. announced today that the company has appointed Paul Daruwala as the company’s president and chief executive officer, effective on October 1st , 2022.

AnHeart Therapeutics and NewG Lab Therapeutics, a subsidiary of NewG Lab Pharma, announced that the Ministry of Food and Drug Safety (MFDS), Republic of Korea has granted the Designation of Orphan Drug (ODD) to taletrectinib, a next generation tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Universal Diagnostics (Universal DX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced the results of a proof of principle study demonstrating that the analysis of microbiome signatures in plasma can assist in early detection of colorectal cancer.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it has signed a definitive agreement to acquire PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry, from funds advised by AUCTUS Capital Partners AG for €1.28 billion in cash, subject to certain customary adjustments.

Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that management will participate in a company overview at the H.C. Wainwright 24th Annual Global Investment Conference.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the closing of the global license agreement with Roche and Genentech, a member of the Roche Group (Genentech), for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ).

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it has entered into a non-dilutive royalty financing agreement with OrbiMed for up to $250 million.